Retatrutide has a long half-life estimated at approximately six days based on phase 2 pharmacokinetic data (Jastreboff et al., NEJM 2023) meaning that drug levels rise gradually and remain relatively stable between weekly doses once a steady state is achieved (typically after approximately four to five half-lives, or around four to five weeks of weekly dosing)
Retatrutide is one of the most actively studied compounds in the metabolic and obesity research literature, following published Phase 2 clinical trial data showing substantial reductions in body weight in human study populations
However, these may not work the same as the brand names have specific formularies that get the results they do
Keeping the weight off afterward presents an entirely different set of considerations that deserve attention before even starting treatment
The program also offers personal guidance, check-ins, and unlimited provider messaging
While each medication has different dosing schedules, pen designs, and clinical indications, the fundamental injection technique is the same: a subcutaneous injection (under the skin) administered once per week
